ArticleNPJ vaccines2020
Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a
Article in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Unveiling the role of outer membrane proteins (OMPs) in biofilm formation and Harnessing them for targeting biofilm-forming bacterial infections.World journal of microbiology & biotechnology · 2026Review
- Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model.NPJ vaccines · 2024Article
- Article
- CT584 Is Not a Protective Vaccine Antigen against Respiratory Chlamydial Challenge in Mice.Vaccines · 2024Article
- Recognition ofInfection and immunity · 2024Article
- Advances inMicroorganisms · 2024Review
- Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.NPJ vaccines · 2024Article
- Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice.Nature communications · 2024Article
- Article
- Efficacy of a synthetic peptide Chlamydia pecorum major outer membrane protein vaccine in a wild koala (Phascolarctos cinereus) population.Scientific reports · 2023Article
- Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge withPathogens (Basel, Switzerland) · 2023Article
- DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection.Applied microbiology and biotechnology · 2022Article
- Combining Cellular Immunology With RNAseq to Identify Novel Chlamydia T-Cell Subset Signatures.The Journal of infectious diseases · 2022Article
- Induction of Protection in Mice against aVaccines · 2021Article
- Article
- Th1/Th17 T cell Tissue-Resident Immunity Increases Protection, But Is Not Required in a Vaccine Strategy Against Genital Infection WithFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Implementation of a vaccine is likely the best approach to curtail
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.